EFG
BMRN icon

Everhart Financial Group’s BioMarin Pharmaceuticals BMRN Stock Holding History

Everhart Financial Group’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$400K Buy
6,995
+1,784
+34% +$97.7K 0.03% 307
2026
Q1 		$294K Buy
+5,211
New +$304K 0.03% 361
2025
Q2 		– Sell
-3,180
Closed -$225K – 341
2025
Q1 		$225K Buy
+3,180
New +$214K 0.03% 310

Other funds holding BMRN

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
RRAM
River Road Asset Management Louisville, Kentucky $8.99B AUM 12.83% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
PCM
Peregrine Capital Management Minneapolis, Minnesota $3.08B AUM 29.51% 1-Year Est. Return
CF
Covea Finance Paris, France $3.17B AUM 35.01% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
SAM
Secure Asset Management Troy, Michigan $714M AUM 27.91% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Everhart Financial Group's BMRN Position: Q2 2026 in Review

Everhart Financial Group increased its BioMarin Pharmaceuticals (BMRN) stake by 34% in Q2 2026, buying an estimated $97.7K and bringing the position to 6,995 shares worth $400K. The position accounts for 0.03% of the portfolio, ranked #307.

Everhart Financial Group first reported a position in BMRN in Q1 2025 and has held it in 3 quarters since. 81 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • Everhart Financial Group held 6,995 shares of BioMarin Pharmaceuticals worth $400K as of Q2 2026.
  • Everhart Financial Group bought 1,784 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $97.7K.
  • BioMarin Pharmaceuticals made up 0.03% of Everhart Financial Group's portfolio in Q2 2026, its #307 holding.
  • Everhart Financial Group first reported a position in BioMarin Pharmaceuticals in Q1 2025 and has held it in 3 quarters since.
  • 81 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Everhart Financial Group's 13F filing for Q2 2026, filed 9 Jul 2026.